Improved CAR-T cell targeting of cancer

Description of the granted funding

Chimeric antigen receptor (CAR)-T cell therapy is a promising new approach for treating cancer, where an engineered CAR molecule is introduced into patient's immune cells to direct them to destroy cancer cells. CAR-T cell therapy has been very successful in treating leukemias and lymphomas. However, most cancers lack any truly cancer-specific determinants, and it has been difficult to create CAR-T cells that would efficiently kill cancer without attacking healthy tissues. Our laboratory has developed a new and highly tunable targeting technology based on a small protein module, known as the SH3 domain. We have already shown that using modified SH3 domains it is possible to create CAR-T cells that can sense even relative differences between cancer and normal cell surface structures. Here we propose a series of experiments designed to exploit this opportunity in order to develop potent but safe CAR-T cell therapies for ovarian and other cancers that have remained difficult to treat.
Show more

Starting year

2020

End year

2024

Granted funding

Kalle Saksela Orcid -palvelun logo
518 340 €

Funder

Research Council of Finland

Funding instrument

Academy projects

Other information

Funding decision number

331787

Fields of science

Biomedicine

Research fields

Biolääketieteet

Identified topics

cancer